Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

OBJECTIVES: Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has been defined, based on the first-in-man trial conducted in the USA and Europe. We carri...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Yamazaki, Kentaro, Tsushima, Takahiro, Naito, Tateaki, Matsubara, Nobuaki, Watanabe, Morihiro, Sarholz, Barbara, Johne, Andreas, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401714/
https://www.ncbi.nlm.nih.gov/pubmed/32328660
http://dx.doi.org/10.1093/jjco/hyaa042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401714/
https://www.ncbi.nlm.nih.gov/pubmed/32328660
http://dx.doi.org/10.1093/jjco/hyaa042

Ejemplares similares